MedTrace Logo

BREAST CANCER AND EXERCISE

NCT00639210 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 573

Last updated 2019-02-26

No results posted yet for this study

Summary

A Finnish Breast Cancer Group Study (BREX 01-2004). A multicenter phase III open randomised trial of the efficacy of exercise in the prevention of long-term adverse effects of adjuvant treatments and breast cancer recurrences in women with primary breast cancer. The aim of the study is to investigate whether regular exercise training could reduce the long-term side effects of adjuvant treatments of primary breast cancer and improve quality of life and well being.

Conditions

  • Prevent Osteoporosis and Osteoporotic Fractures
  • Improve Quality of Life
  • Improve Weight Control, and Muscular and Cardiovascular Fitness
  • Help the Patients to Return to Working Life
  • Reduce the Risk of Breast Cancer Recurrence
  • Reduce All-cause Mortality in Patients With Primary Breast Cancer

Interventions

OTHER

supervised training

Design: supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.Content: The supervised training of the exercise group consists of two different classes alternating at four week periods; step aerobics class and circuit training class. The 60-minute aerobics and circuit training classes also include warming-up and cooling-down periods both lasting 10-15 minutes.

Sponsors & Collaborators

  • Finnish Breast Cancer Group

    lead OTHER

Principal Investigators

  • Tiina Saarto, MD, PhD · Helsinki University Central Hospital, Department of Oncology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
68 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-09-30
Completion
2007-09-30

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00639210 on ClinicalTrials.gov